Overcoming efficacy, safety, and manufacturing hurdles through innovative personalized cancer vaccine design ...

The lifespan of companion animals remains shorter compared to humans. Unlike the rapid advancement in medical technology that ...

Patients with non-squamous non-small cell cancer may achieve similar outcomes with a subcutaneous formulation of the immunotherapy toripalimab as with IV administration.

Halozyme Therapeutics has expanded its portfolio of drug delivery technologies for a second time in a few months with the acquisition of Surf Bio and its subcutaneous injection platform. The ...